Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

Fig. 3

Comparison of individual pCR and non-pCR patients. a Cell surface GRP78 expression in PBMC subpopulations in each patient after the taxane phase (P3) comparing patients who achieved pCR with non-pCR patients. b Representative FACS data dot blot of one pCR patient showing the FMO control for each PBMC subpopulation at the baseline (P1), after AC treatment (P2), and after taxanes treatment (P3)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us